FG5865

{{Short description|Alcoholism drug}}

{{cs1 config|name-list-style=vanc|display-authors=6}}

{{Infobox drug

| drug_name = FG5865

| image =FG5865.svg

| width = 250px

| caption =

| pronounce =

| tradename =

| Drugs.com =

| MedlinePlus =

| licence_CA =

| licence_EU =

| DailyMedID =

| licence_US =

| pregnancy_AU =

| pregnancy_category =

| dependency_liability =

| addiction_liability =

| routes_of_administration =

| class =

| ATC_prefix =

| ATC_suffix =

| legal_status =

| bioavailability =

| protein_bound =

| metabolism =

| metabolites =

| onset =

| elimination_half-life =

| duration_of_action =

| excretion =

| CAS_number =

| CAS_supplemental =

| PubChem = 10026785

| IUPHAR_ligand =

| DrugBank =

| ChemSpiderID = 8202356

| UNII =

| KEGG =

| ChEBI =

| ChEMBL =

| NIAID_ChemDB =

| PDB_ligand =

| synonyms =

| IUPAC_name = 2-[4-[4,4-Bis(4-fluorophenyl)butyl]piperazin-1-yl]pyridine-3-carboxamide

| C=26 | H=28 | F=2 | N=4 | O=1

| SMILES =C1CN(CCN1CCCC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C4=C(C=CC=N4)C(=O)N

| StdInChI = 1S/C26H28F2N4O/c27-21-9-5-19(6-10-21)23(20-7-11-22(28)12-8-20)4-2-14-31-15-17-32(18-16-31)26-24(25(29)33)3-1-13-30-26/h1,3,5-13,23H,2,4,14-18H2,(H2,29,33)

| StdInChIKey = KLMRSRHIWFLPBI-UHFFFAOYSA-N

}}

FG5865 is from the diphenylbutylpiperazine class of agents. It is a 5-HT1A agonist and a 5-HT2A antagonist.{{cite journal | vauthors = Myers RD | title = New drugs for the treatment of experimental alcoholism | journal = Alcohol | location = Fayetteville, N.Y. | volume = 11 | issue = 6 | pages = 439–451 | date = 1994 | pmid = 7865140 | doi = 10.1016/0741-8329(94)90064-7 | department = review | publication-place = Fayetteville, N.Y. }}

It is believed to be an anxiolytic agent with treatment in substance abuse disorders particularly alcoholism.{{cite journal | vauthors = Hjorth S, Pettersson G | title = 5-HT1A autoreceptor-mediated effects of the amperozide congeners, FG5865 and FG5893, on rat brain 5-hydroxytryptamine neurochemistry in vivo | journal = European Journal of Pharmacology | volume = 238 | issue = 2–3 | pages = 357–367 | date = July 1993 | pmid = 7691622 | doi = 10.1016/0014-2999(93)90867-H }}{{cite journal | vauthors = ((Long, T.)) | title = Alcohol intake in high alcohol drinking (HAD) rats is suppressed by FG5865, a novel 5-HT1A agonist/5-HT2 antagonist | journal = Pharmacology Biochemistry and Behavior | volume = 53 | issue = 1 | pages = 33–40 | date = January 1996 | pmid = 8848457 | doi = 10.1016/0091-3057(95)00195-6 }}

There is evidence to suggest that FG5865 is a SNDRI.{{cite journal | vauthors = Pettersson E | title = Studies of four novel diphenylbutylpiperazinepyridyl derivatives on release and inhibition of reuptake of dopamine, serotonin and noradrenaline by rat brain in vitro | journal = European Journal of Pharmacology | volume = 282 | issue = 1–3 | pages = 131–135 | date = August 1995 | pmid = 7498267 | doi = 10.1016/0014-2999(95)00300-A }}